Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: a GERCOR study

Author： Hebbar Mohamed  

Publisher： Maney Publishing

ISSN： 1973-9478

Source： Journal of Chemotherapy, Vol.25, Iss.2, 2013-04, pp. : 104-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer

By Duffour Jacqueline   Gourgou Sophie   Desseigne Françoise   Debrigode Charles   Mineur Laurent   Pinguet Frédéric   Poujol Sylvain   Chalbos Patrick   Bressole Françoise   Ychou Marc  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 3, 2007-08 ,pp. : 383-389

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

By Hebbar Mohamed   Tournigand Christophe   Lledo Gérard   Mabro May   André Thierry   Louvet Christophe   Aparicio Thomas   Flesch Michel   Varette Charles   de Gramont Aimery   Group (GERCOR) Oncology  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 154-159

Informa Healthcare

Access to resources Recommend Favorite

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

By Maindrault-Goebel F.   de Gramont A.   Louvet C.   Andre T.   Carola E.   Mabro M.   Artru P.   Gilles V.   Lotz J.P.   Izrael V.   Krulik M.   for the Oncology Multidisciplinary Research Group GERCOR  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 1000-1005

Elsevier

Access to resources Recommend Favorite

A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial

By Ychou Marc   Rivoire Michel   Thezenas Simon   Quenet François   Delpero Jean-Robert   Rebischung Christine   Letoublon Christian   Guimbaud Rosine   Francois Eric   Ducreux Michel   Desseigne Françoise   Fabre Jean-Michel   Assenat Eric  

Annals of Surgical Oncology, Vol. 20, Iss. 13, 2013-12 ,pp. : 4289-4297

Springer Publishing Company

Access to resources Recommend Favorite

Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

By                    

Oncology Letters, Vol. 2, Iss. 3, 2011-01 ,pp. : 493-498

Spandidos Publications

Access to resources Recommend Favorite